Rapid emergence of new variants of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has prompted an urgent need for the development of broadly applicable and …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) neutralizing antibodies
are shown to be effective therapeutics for providing coronavirus disease 2019 (COVID‐19) …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …

Introduction The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants has caused unprecedented health and socioeconomic crises, necessitating …

Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

Monoclonal antibodies are a promising approach to treat COVID-19, however the
emergence of SARS-CoV-2 variants has challenged the efficacy and future of these …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …